2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
Key PointsJohnson & Johnson’s medtech business is experiencing turbulence, but the company has what it takes to overcome it.
Key PointsJohnson & Johnson’s medtech business is experiencing turbulence, but the company has what it takes to overcome it.